TrialArthritis research & therapy2023

Efficacy and safety of upadacitinib in patients with ankylosing spondylitis refractory to biologic therapy: 1-year results from the open-label extension of a phase III study.

Xenofon Baraliakos et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.